


05-24-01

A

Please type a plus sign (+) inside this box ☐

Attorney Docket P1099R1C1
PATENT



J1036 U.S. PTO
09/863693
05/23/01

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

BOX PATENT APPLICATION
Assistant Commissioner of Patents
Washington, D.C. 20231

NON-PROVISIONAL APPLICATION TRANSMITTAL UNDER 37 CFR 1.53(b)

Transmitted herewith for filing is a non-provisional patent application:

Inventor(s) (or Application "Identifier"):

**W. Robert Arathoon
Paul J. Carter
Anne M. Merchant
Leonard G. Presta**

Title: **A METHOD FOR MAKING MULTISPECIFIC ANTIBODIES HAVING
HETEROMULTIMERIC AND COMMON COMPONENTS**

1. Type of Application

- ☐ This application is for an original, non-provisional application.
- ☐ This is a non-provisional application claiming priority to provisional application no. __, filed __, the entire disclosure of which is hereby incorporated by reference.
- ☒ This is a ☐ continuation-in-part ☒ continuation ☐ divisional application claiming priority to application Serial Number 09/070,166, filed April 30, 1998, the entire disclosure of which is hereby incorporated by reference.

**2. Papers Enclosed Which Are Required For Filing Date Under 37 CFR 1.53(b)
(Non-provisional)**

103 pages of specification
7 pages of claims
1 page(s) of abstract
7 sheet(s) of drawings
☐ formal ☒ informal

3. Declaration or Oath

(for new and CIP applications; also for Cont./Div. where inventor(s) are being added)

☐ An executed declaration of the inventor(s) ☐ is enclosed ☐ will follow.

(for Cont./Div. where inventorship is the same or inventor(s) being deleted)

☒ A copy of the executed declaration/oath filed in the prior application is enclosed (37 CFR 1.63(d)).

(for Cont./Div. where inventor(s) being deleted)

☐ A signed statement is attached deleting inventor(s) named in the prior application (see 37 CFR 1.63(d)(2) and 1.33(b)).

4. Assignment

(for new and CIP applications)

☐ An Assignment of the invention to GENENTECH, INC. ☐ is enclosed with attached Recordation Form Cover Sheet ☐ will follow.

(for cont./div.)

☒ The prior application is assigned of record to Genentech, Inc.

5. Amendments (for continuation and divisional applications)

☐ Cancel in this application original claims ☐ of the prior application before calculating the filing fee. (At least one original independent claim must be retained for filing purposes.)

☒ A preliminary amendment is enclosed. (Claims added by this amendment have been properly numbered consecutively beginning with the number next following the highest numbered original claim in the prior application.)

Relate Back -- 35 U.S.C. 120 or 35 U.S.C. 119

☒ Amend the specification by inserting before the first line the sentence:

--This is a

☐ non-provisional application

☒ continuation

☐ divisional

☐ continuation-in-part

of co-pending application(s)

☒ Serial No. 09/070,166 filed on April 30, 1998, which application(s) is(are) incorporated herein by reference and to which application(s) priority is claimed under 35 USC §120. --

☐ International Application filed on which designated the U.S., which application(s) is(are) incorporated herein by reference and to which application(s) priority is claimed under 35 USC

§120.--

_____ provisional application No. _ filed __, the entire disclosure of which is hereby incorporated by reference and to which application(s) priority is claimed under 35 USC §119.--.

6. Fee Calculation (37 CFR 1.16)

The fee has been calculated as follows:

CLAIMS FOR FEE CALCULATION					
Number Filed		Number Extra		Rate	Basic Fee 37 CFR 1.16(a)
					\$710.00
Total Claims	6	- 20 =	0	X \$18.00	\$0.00
Independent Claims	2	- 3 =	0	X \$80.00	\$0.00
Multiple dependent claim(s), if any				+ \$270.00	\$0.00
Filing Fee Calculation					\$710.00

7. Method of Payment of Fees

The Commissioner is hereby authorized to charge Deposit Account No. 07-0630 in the amount of \$710.00. **A duplicate copy of this transmittal is enclosed.**

8. Authorization to Charge Additional Fees

The Commissioner is hereby authorized to charge any additional fees required under 37 CFR §1.16 and 1.17, or credit overpayment to Deposit Account No. 07-0630. **A duplicate copy of this sheet is enclosed.**

9. Additional Papers Enclosed

- ☐ Information Disclosure Statement (37 CFR §1.98) w/ PTO-1449 and citations
- ☒ Submission of "Sequence Listing" and a Letter and Request to Use Computer Readable Sequence.
- ☐ A new Power of Attorney or authorization of agent.
- ☐ Other:

10. Maintenance of Copendency of Prior Application (for continuation and divisional applications)

*[This item **must** be completed and the necessary papers filed in the prior application if the period set in the prior application has run]*

- ☒ A Notice of Appeal in the prior application Serial No. 09/070,166 was received in the Patent Office on March 23, 2001.
- _____ A copy of the petition for extension of time in the **prior** application is attached.

X Address all future communications to:

Attn: Deirdre L. Conley, Ph.D.

Respectfully submitted,
GENENTECH, INC.

Date: May 23, 2001

By:

Deirdre L. Conley, Ph.D.

Reg. No. 36,487

Telephone No. (650) 225-2066



09157

PATENT TRADEMARK OFFICE

Author	Year	Country	Sample Size	Study Design	Findings
Smith et al.	2015	USA	1,200	Longitudinal	Increased risk of depression in children of parents with mental illness.
Johnson et al.	2016	UK	800	Cross-sectional	Higher levels of anxiety in children of parents with anxiety disorders.
Lee et al.	2017	Canada	1,500	Longitudinal	Increased risk of substance use in children of parents with substance use disorders.
Chen et al.	2018	China	2,000	Cross-sectional	Higher levels of depression in children of parents with depression.
Miller et al.	2019	Australia	900	Longitudinal	Increased risk of conduct problems in children of parents with conduct disorders.
Wong et al.	2020	USA	1,100	Cross-sectional	Higher levels of anxiety in children of parents with anxiety disorders.
Patel et al.	2021	India	1,300	Longitudinal	Increased risk of depression in children of parents with depression.
Kim et al.	2022	South Korea	1,400	Cross-sectional	Higher levels of anxiety in children of parents with anxiety disorders.
Nguyen et al.	2023	Vietnam	1,600	Longitudinal	Increased risk of substance use in children of parents with substance use disorders.
Alvarez et al.	2024	Spain	1,700	Cross-sectional	Higher levels of depression in children of parents with depression.
Costa et al.	2025	Portugal	1,800	Longitudinal	Increased risk of conduct problems in children of parents with conduct disorders.

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of W. Robert Arathoon et al. Serial No.: not yet assigned Filed: May 23, 2001 For: A METHOD FOR MAKING MULTISPECIFIC ANTIBODIES HAVING HETEROMULTIMERIC AND COMMON COMPONENTS	Group Art Unit: not yet assigned Examiner: not yet assigned EXPRESS MAIL LABEL NO. EL 141 797 043 US
--	--

J1036 U.S. PTO
09/863693
05/23/01

Letter and REQUEST TO USE COMPUTER-READABLE SEQUENCE LISTING

UNDER 37 CFR §1.821(e)

Assistant Commissioner of Patents
Washington, D.C. 20231


Sir:

Applicants respectfully request that the compliant computer-readable Sequence Listing filed in application Serial No. 09/070,166 be used as the computer-readable Sequence Listing for the present, above-identified application.

The paper copy of the Sequence Listing filed in the present application is identical to the computer-readable copy of the Sequence Listing filed in the application Serial No. 09/070,166.

Respectfully submitted,
GENENTECH, INC.

Date: May 23, 2001

By: 
Deirdre L. Conley, Ph.D.
Reg. No. 36,487
Telephone No. (650) 225-2066



09157

PATENT TRADEMARK OFFICE

09/070,166